Skip to main content

Day: March 30, 2022

Proactive news headlines including Orgenesis, Numinus Wellness, ElectraMeccanica Vehicles, Red Pine Exploration and Equity Metals

New York , March 30, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globe click here Amarillo Gold says its acquisition by a subsidiary of Hochschild Mining and the spin-out of Lavras Gold is expected to occur on April 1, 2022 click here Cypress Development announces results from Lithium Extraction Pilot Plant in Nevada click here Kontrol Technologies Corp secures $16 million HVAC and Automation project for a new high-rise building in the Greater Toronto Area click here Red Pine Exploration posts more positive drill results from Wawa gold project, Ontario click here ElectraMeccanica Vehicles announces appointment...

Continue reading

iSIGN Media Announces the Signing of a Licensing Agreement with SIMBL for Advanced Technologies and Associated Platforms

TORONTO, March 30, 2022 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions, announced that on March 30, 2022 the Company signed an exclusive worldwide Licensing Agreement (“Agreement”) in perpetuity with SIMBL Business Enablement Inc. (“SIMBL”) for its Passive Historical Contact Tracing (“PHACT”) and underlying framework, including SPE Asset Management System for smart location analytics and monitoring Intellectual Property (”IP”). The PHACT IP provides smart location analytics and monitoring. Conceived as a contact tracing platform, the overall platform enables one to monitor the movement, congregation behaviours, and general movements of individuals within a monitored space, while maintaining...

Continue reading

VOW ASA: Share buy-back programme finalised

VOW ASA (“VOW”) has on 30 March 2022 finalised the repurchase of shares under the share buy-back programme announced on 15 March 2022. The programme was carried out by SpareBank 1 Markets AS. The total programme comprised 1,000,000 shares repurchased in the market for a total consideration of NOK 21,765,251. The weighted average price for the shares was NOK 21,7653. For further information, please contact: Erik Magelssen, CFOVow ASATel: +47 928 88 728Email: erik.magelssen@vowasa.comAbout Vow ASA Vow and its subsidiaries Scanship and Etia are passionate about preventing pollution. The company’s world leading solutions convert biomass and waste into valuable resources and generate clean energy for a wide range of industries. Cruise ships on every ocean have Vow technology inside which processes waste and purifies wastewater....

Continue reading

Fluxys Belgium: Regulated information – 2021 results

30 March 2022 6:30 p.m. – Regulated information: overview of the 2021 annual resultsConsolidated turnover increases to €573.2 million (2020: €560.6 million) and consolidated net income increases to €75.5 million (2020: €73.2 million) Fluxys Belgium supports those impacted by the floods Ready for the network of the future: ambition to have the first hydrogen and/or CO2 infrastructure ready for use in 2026 On track to halve our greenhouse gas emissions by 2025 Proposal to the Annual General Meeting on 10 May 2022: gross dividend of €1.38 per share (2020: €1.37 per share) Transmission: our network as a hub for Germany and the Netherlands LNG terminallingMore shipping traffic as well as loading operations for LNG trailers Bio-LNG available Additional regasifiers with seawater and extra truck loading stations under construction...

Continue reading

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received an €8 million milestone payment upon initiation of the expansion phase of the Phase 1 trial of anti-SIRPα BI 765063 (CD47/SIRPα pathway) in advanced solid tumor patients being conducted with partner Boehringer Ingelheim, after positive dose escalation results. Received a €5 million milestone payment upon initiation of a Phase 2 trial with OSE-127/S95011 in Sjögren’s syndrome with partner Servier, the sponsor of the trial. Received a €7 million milestone payment upon signature of a license agreement with Veloxis Pharmaceuticals Inc. for FR104, anti-CD28, in transplant indications; an additional €5 million milestone payment was made in early...

Continue reading

Press release – Orange’s Board of Directors proposes Jacques Aschenbroich as a Director and future Group Non-Executive Chairman

Press ReleaseParis, 30 March 2022 Orange’s Board of Directors proposes Jacques Aschenbroich as a Director and future Group Non-Executive Chairman The Board of Directors of Orange, at its meeting on 30 March 2022, proposed Jacques Aschenbroich as a new Director of the Group and, from 19 May, as Chairman of the Board. The nomination of Jacques Aschenbroich as a Director will be submitted to the Annual General Meeting of shareholders that will take place on 19 May, following which the Board would meet to elect him as its Non-Executive Chairman. The Board of Directors expresses its thanks to the Group’s Governance and Corporate Social and Environmental Responsibility committee, which oversees appointments, along with the lead independent Director, for conducting a rigorous selection process. The Board is also proposing to modify the Company’s...

Continue reading

Changed Outlook for the financial year 2021/22

Changed Outlook for the financial year 2021/22 The Board of Directors of Rovsing A/S has today approved an adjustment to the expected outlook for the financial year 2021/22. Adjusted OutlookBased on the year to date performance of the financial year beginning 1 July 2021 and with further comprehensive delays in primarily two large projects, the Company will not be able to recover the delayed revenue before the end on this financial year ending 30 June 2022. The planned activities on the large Galileo 2nd Gen EGSE project have shifted significantly due to delayed incoming Customer requirement updates. In addition, NASA and ESA have announced a 1-year overall postponement of the Mars Sample Return mission impacting equally Roving’s deliveries on this mission. Due to the significant shifts of deliveries, the outlook for 2021/22 is adjusted...

Continue reading

Record high turnover and earnings in 2021

RECORD HIGH TURNOVER AND EARNINGS IN 2021 Turnover:                  €2,696.6 million (+23.1%)     Net profit:                     €75.7 million (+83.3%)         The Board of Directors of SYNERGIE, chaired by Victorien Vaney, met on 30 March 2022 and approved the full-year financial statements for the period ended 31 December 2021. The auditing procedures for these financial statements are complete and the corresponding reports are being issued.Consolidated – in € million 2021 2020 2019       Turnover 2,696.6 2,190.3 2,642.3Ebitda 147.3 112.7 138.5Current operating profit (1) 124.3 89.5 121.7Operating profit 116.5 77.6 114.0Financial expense (1.0) (3.2) (1.4)Profit before tax 115.4 74.4 112.6Tax expense (2) (39.7) (33.2) (49.2)Net...

Continue reading

Egide: 2021 FY results

Bollène, March 30, 2022 – 06 :00 pm (CET)Press Release 2021 FY RESULTSDespite the continued difficulties resulting from the Covid pandemic, the Egide Group has continued resiliency providing growth in 2021.2021 revenues: €32.50m (+8.5% /2020) EBITDA after rent: €1.5m (vs. €3.8m in 2020). Group Net Profit: €0.05m (vs. €0.98m in 2020). The Egide SA and Egide USA business units are growing (+ 5.8% and +31.7% respectively), while Santier is essentially neutral.2022 outlook:There is optimism as the order intake at the end of 2021, driven largely by the Defense sector, provides a solid foundation for growth in 2022. Project to convert fixed asset into cash with the sale-leaseback of the Cambridge facility Labor shortages in the US, and risks related to Covid-19 lingering crisis, will need to be overcome in 2022 to meet expectations....

Continue reading

LECTRA: Availability of 2021 Annual Financial Report

Lectra: Availability of 2021 Annual Financial Report Paris, March 30, 2022 – Lectra announces that its 2021 Annual Financial Report has been released and filed with the French Financial Markets Authority (Autorité des marchés financiers). The 2021 Annual Financial Report containing the Management Report, the Report on Corporate Governance and Non-financial Statement is now available in the ESEF format (European Single Electronic Format) and in PDF version on the company’s website: https://www.lectra.com/fr/investisseurs. A condensed English version of the Annual Financial Report 2021 is also available on the company’s website: https://www.lectra.com/en/investors. About Lectra: For companies that breathe life into our wardrobes, car interiors, furniture and more, Lectra crafts the premium technologies that facilitate the digital...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.